503 related articles for article (PubMed ID: 26752261)
1. PLGA particulate delivery systems for subunit vaccines: Linking particle properties to immunogenicity.
Silva AL; Soema PC; Slütter B; Ossendorp F; Jiskoot W
Hum Vaccin Immunother; 2016 Apr; 12(4):1056-69. PubMed ID: 26752261
[TBL] [Abstract][Full Text] [Related]
2. Functional characterization of biodegradable nanoparticles as antigen delivery system.
Petrizzo A; Conte C; Tagliamonte M; Napolitano M; Bifulco K; Carriero V; De Stradis A; Tornesello ML; Buonaguro FM; Quaglia F; Buonaguro L
J Exp Clin Cancer Res; 2015 Oct; 34():114. PubMed ID: 26444005
[TBL] [Abstract][Full Text] [Related]
3. Poly-(lactic-co-glycolic-acid)-based particulate vaccines: particle uptake by dendritic cells is a key parameter for immune activation.
Silva AL; Rosalia RA; Varypataki E; Sibuea S; Ossendorp F; Jiskoot W
Vaccine; 2015 Feb; 33(7):847-54. PubMed ID: 25576216
[TBL] [Abstract][Full Text] [Related]
4. Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations.
Hamdy S; Haddadi A; Hung RW; Lavasanifar A
Adv Drug Deliv Rev; 2011 Sep; 63(10-11):943-55. PubMed ID: 21679733
[TBL] [Abstract][Full Text] [Related]
5. pH-Responsive Poly(D,L-lactic-co-glycolic acid) Nanoparticles with Rapid Antigen Release Behavior Promote Immune Response.
Liu Q; Chen X; Jia J; Zhang W; Yang T; Wang L; Ma G
ACS Nano; 2015 May; 9(5):4925-38. PubMed ID: 25898266
[TBL] [Abstract][Full Text] [Related]
6. Targeting human dendritic cells via DEC-205 using PLGA nanoparticles leads to enhanced cross-presentation of a melanoma-associated antigen.
Saluja SS; Hanlon DJ; Sharp FA; Hong E; Khalil D; Robinson E; Tigelaar R; Fahmy TM; Edelson RL
Int J Nanomedicine; 2014; 9():5231-46. PubMed ID: 25419128
[TBL] [Abstract][Full Text] [Related]
7. "Pathogen-mimicking" nanoparticles for vaccine delivery to dendritic cells.
Elamanchili P; Lutsiak CM; Hamdy S; Diwan M; Samuel J
J Immunother; 2007; 30(4):378-95. PubMed ID: 17457213
[TBL] [Abstract][Full Text] [Related]
8. Surface modification of poly(D,L-lactic-co-glycolic acid) nanoparticles with protamine enhanced cross-presentation of encapsulated ovalbumin by bone marrow-derived dendritic cells.
Han R; Zhu J; Yang X; Xu H
J Biomed Mater Res A; 2011 Jan; 96(1):142-9. PubMed ID: 21105162
[TBL] [Abstract][Full Text] [Related]
9. Particulate vaccines: on the quest for optimal delivery and immune response.
De Temmerman ML; Rejman J; Demeester J; Irvine DJ; Gander B; De Smedt SC
Drug Discov Today; 2011 Jul; 16(13-14):569-82. PubMed ID: 21570475
[TBL] [Abstract][Full Text] [Related]
10. Cross-Linked Peptide Nanoclusters for Delivery of Oncofetal Antigen as a Cancer Vaccine.
Tsoras AN; Champion JA
Bioconjug Chem; 2018 Mar; 29(3):776-785. PubMed ID: 29436221
[TBL] [Abstract][Full Text] [Related]
11. Synthetic long peptide-based vaccine formulations for induction of cell mediated immunity: A comparative study of cationic liposomes and PLGA nanoparticles.
Varypataki EM; Silva AL; Barnier-Quer C; Collin N; Ossendorp F; Jiskoot W
J Control Release; 2016 Mar; 226():98-106. PubMed ID: 26876760
[TBL] [Abstract][Full Text] [Related]
12. Particulate Systems Based on Poly(Lactic-co-Glycolic)Acid (pLGA) for Immunotherapy of Cancer.
Rahimian S; Fransen MF; Kleinovink JW; Amidi M; Ossendorp F; Hennink WE
Curr Pharm Des; 2015; 21(29):4201-16. PubMed ID: 26323429
[TBL] [Abstract][Full Text] [Related]
13. PLGA particulate subunit tuberculosis vaccines promote humoral and Th17 responses but do not enhance control of Mycobacterium tuberculosis infection.
Ashhurst AS; Parumasivam T; Chan JGY; Lin LCW; Flórido M; West NP; Chan HK; Britton WJ
PLoS One; 2018; 13(3):e0194620. PubMed ID: 29554138
[TBL] [Abstract][Full Text] [Related]
14. CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses.
Rosalia RA; Cruz LJ; van Duikeren S; Tromp AT; Silva AL; Jiskoot W; de Gruijl T; Löwik C; Oostendorp J; van der Burg SH; Ossendorp F
Biomaterials; 2015 Feb; 40():88-97. PubMed ID: 25465442
[TBL] [Abstract][Full Text] [Related]
15. Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses.
Diwan M; Elamanchili P; Lane H; Gainer A; Samuel J
J Drug Target; 2003; 11(8-10):495-507. PubMed ID: 15203918
[TBL] [Abstract][Full Text] [Related]
16. Peptide/protein vaccine delivery system based on PLGA particles.
Allahyari M; Mohit E
Hum Vaccin Immunother; 2016 Mar; 12(3):806-28. PubMed ID: 26513024
[TBL] [Abstract][Full Text] [Related]
17. Poly(lactic acid) and poly(lactic-co-glycolic acid) particles as versatile carrier platforms for vaccine delivery.
Pavot V; Berthet M; Rességuier J; Legaz S; Handké N; Gilbert SC; Paul S; Verrier B
Nanomedicine (Lond); 2014 Dec; 9(17):2703-18. PubMed ID: 25529572
[TBL] [Abstract][Full Text] [Related]
18. Pulmonary delivery of DNA encoding Mycobacterium tuberculosis latency antigen Rv1733c associated to PLGA-PEI nanoparticles enhances T cell responses in a DNA prime/protein boost vaccination regimen in mice.
Bivas-Benita M; Lin MY; Bal SM; van Meijgaarden KE; Franken KL; Friggen AH; Junginger HE; Borchard G; Klein MR; Ottenhoff TH
Vaccine; 2009 Jun; 27(30):4010-7. PubMed ID: 19389445
[TBL] [Abstract][Full Text] [Related]
19. Administration Routes of Polyethylenimine-Coated PLGA Nanoparticles Encapsulating Angelica Sinensis Polysaccharide Vaccine Delivery System Affect Immune Responses.
Gu P; Zhang Y; Cai G; Liu Z; Hu Y; Liu J; Wang D
Mol Pharm; 2021 Jun; 18(6):2274-2284. PubMed ID: 33926191
[TBL] [Abstract][Full Text] [Related]
20. Nanoparticles with CD44 Targeting and ROS Triggering Properties as Effective in Vivo Antigen Delivery System.
Liang X; Li X; Duan J; Chen Y; Wang X; Pang L; Kong D; Song B; Li C; Yang J
Mol Pharm; 2018 Feb; 15(2):508-518. PubMed ID: 29323913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
